A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Colorado Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Protara Therapeutics
A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer
Enrollment Form
This study is currently enrolling.
